Just Medicine Campaign
The DGSOM AMSA chapter is proud to partner with AMSA National in launching the new Just Medicine Campaign!
Campaign Goals:
- Advocate for affordable prescription medicines, specifically H.R. 1046 (the Medicare Negotiation & Competitive Licensing Act) & H.R. 3 (Elijah E. Cummings Lower Drug Prices Now Act)
- Raise awareness about how healthcare policies are influenced by high pharmaceutical drug prices
- Mobilize students and members of the community to engage with policymakers about these issues
- Assess and highlight the influence of pharmaceutical lobbying in policymaking
- Organize advocacy workshops to empower students and give them the tools they need to advocate for change

More about H.R. 1046:
Key points of the bill:
-
Under H.R. 1046, the Secretary of Health & Human Services would be required to negotiate prescription medication prices directly with pharmaceutical companies, on behalf of Medicare Part D
-
If negotiations fail, a competitive license will be issued to generic manufacturers in order to produce a more affordable version of the medication
-
In the event that a competitive license is issued:
-
Reasonable compensation will be provided to the original pharmaceutical company to minimize profit loss in the interim
-
An interim price for the medication in question will be set based on international references
-
-
"Pay-for-delay" and other anticompetitive behaviors in the pharmaceutical industry would be prohibited
Support:
-
128 co-sponsors in the House of Representatives
-
Endorsed by the Congressional Progressive Caucus
-
90% of Democratic and Republican voters support the concept of Medicare negotiation with pharmaceutical companies
Download AMSA National's H.R. 1046 fact sheet or read the full text bill.
More about H.R. 3:
Key Points of the bill:
- H.R. 3 is House Speaker Nancy Pelosi's drug pricing bill which would allow Medicare to negotiate prices for 250 of the most expensive prescription drugs in the market (annually)
- Prices (based on an "international pricing index") would then be applied to these drugs in the private health insurance market as well
- This bill would also penalize pharmaceutical companies who do not participate in negotiations with taxes that increase each quarter until they participate
- It would also penalize companies that raise medication prices at greater rates than the inflation rate
- It creates an out-of-pocket maximum of $2,000 for Medicare benificiaries (currently no maximum)
- This bill also calls for reinvesting government and Medicare savings from lower drug prices into NIH research for novel treatments
Support:
- H.R. 3 passed the House of Representatives on December 12, 2019
Read the full text bill and stay updated on H.R. 3's progress.
Stay informed!
To find your senator, visit https://www.senate.gov/
To find your representative, visit https://www.house.gov/
To learn about a bill, visit https://www.congress.gov/
Get involved!
Please contact us if you'd like to get involved in this campaign or receive updates about related events such as advocacy trainings, lobby visits, or lunch talks.